{"id":"NCT00286091","sponsor":"Amgen","briefTitle":"Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-01-24","primaryCompletion":"2010-07-30","completion":"2014-04-09","firstPosted":"2006-02-03","resultsPosted":"2015-04-06","lastUpdate":"2018-10-17"},"enrollment":1435,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Hormone Refractory Prostate Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"Denosumab","otherNames":["XGEVAÂ®"]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Denosumb","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to compare the treatment effect of denosumab with placebo on prolonging bone metastasis-free survival in men with hormone refractory (androgen independent) prostate cancer who have no bone metastasis at baseline.","primaryOutcome":{"measure":"Bone Metastasis-free Survival","timeFrame":"From the first dose of investigational product to the primary data cutoff date of 30 July 2010; median time on study was approximately 20 months.","effectByArm":[{"arm":"Placebo","deltaMin":768,"sd":null},{"arm":"Denosumab","deltaMin":897,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0284"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["22093187"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":332,"n":705},"commonTop":["Back pain","Constipation","Arthralgia","Urinary tract infection","Diarrhoea"]}}